Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Military Has First Dibs On New FDA Path With Brain-Controlled Prosthetic

This article was originally published in The Gray Sheet

Executive Summary

While CDRH's innovation initiative is technically in the proposal stage and subject to public comment, the center is moving forward with a pilot run of the new priority-review program.

You may also be interested in...



Thought-Controlled Prosthetics Get US FDA 'Leapfrog' Treatment

A new "leapfrog" draft guidance from the US agency addresses implanted brain-computer interface prosthetic devices, and, specifically, the information sponsors should be prepared to submit for pre-submissions meetings and investigational device exemptions.

FDA Approves Advanced Prosthetic Arm

FDA approved an advanced prosthetic arm from Deka R&D Corp. May 9 that has the ability to translate electrical signals from muscle into complex tasks.

Research In Brief

New obesity device pivotal study and more research news.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel